芪藤壮骨片联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎临床研究

Clinical Study on the Combination of Qiteng Zhuanggu Tablets and Recombinant Human TypeⅡTumorNecrosis Factor Receptor Antibody Fusion Protein in the Treatment of Ankylosing Spondylitis

目的探究芪藤壮骨片联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎的临床疗效。方法选取116例强直性脊柱炎患者作为研究对象,依据患者血清人类白细胞抗原B 27(human leukocyte antigen B 27,HLA-B27)阳性强弱将其分为研究组与对照组,每组58例。对照组采用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗,研究组采用芪藤壮骨片联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗,2组均治疗18个月。比较2组治疗前后的脊柱关节疼痛评分以及炎症相关实验室指标的变化。结果治疗后,2组脊柱关节疼痛评分及HLA-B27和免疫炎症相关指标均较治疗前降低(P均<0.05),且研究组上述评分及实验室指标均明显低于对照组(P均<0.05)。结论芪藤壮骨片联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎能有效减轻患者的脊柱关节疼痛度,并降低炎症相关指标水平。

Objective To explore the clinical efficacy of Qiteng Zhuanggu tablets combined with recombinant human typeⅡtumor necrosis factor receptor antibody fusion protein in the treatment of ankylosing spondylitis.Methods A total of 116 patients with ankylosing spondylitis were selected as the study subjects.They were divided into the study group and the control group based on the strength of their serum human leukocyte antigen B27(HLA-B27)positivity,with 58 cases in each group.The control group was treated with recombinant human typeⅡtumor necrosis factor receptor antibody fusion protein,while the study group was treated with Qiteng Zhuanggu tablets combined with recombinant human typeⅡtumor necrosis factor receptor antibody fusion protein.Both groups were treated for 18 months.The changes of spinal joint pain scores and inflammation related laboratory indicators before and after treatment in the two groups were compared.Results After treatment,the spinal joint pain scores,HLA-B27,and immune inflammation related indicators in both groups decreased compared to those before treatment(P all<0.05),and the above scores and laboratory indicators in the study group were significantly lower than those in the control group(P<0.05).Conclusion The combination of Qiteng Zhuanggu tablets and recombinant human typeⅡtumor necrosis factor receptor antibody fusion protein could effectively alleviate spinal joint pain in patients with ankylosing spondylitis and reduce the level of inflammation related indicators.